BioSig Technologies, Inc. (BSGM)
NASDAQ: BSGM · Real-Time Price · USD
4.600
-0.070 (-1.50%)
At close: Aug 13, 2025, 4:00 PM
4.500
-0.100 (-2.17%)
Pre-market: Aug 14, 2025, 9:11 AM EDT
Company Description
BioSig Technologies, Inc., a medical technology company, provides digital signal processing technology platform services in the United States.
The company offers PURE EP Platform that delivers insights to electrophysiologists for ablation treatments of cardiovascular arrhythmias.
It has a research agreement with Mayo Foundation with the right to sublicense for patent applications in the fields of signal processing, physiologic recording, electrophysiology recording, electrophysiology software, and autonomics to develop, make, and offer for sale.
The company also designs and develops an online platform for real-world asset (RWA) tokenization. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Los Angeles, California.
BioSig Technologies, Inc.
| Country | United States |
| Founded | 2009 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 5 |
| CEO | Karl McPhie |
Contact Details
Address: 12424 Wilshire Blvd, Suite 745 Los Angeles, California 90025 United States | |
| Phone | 203 409 5444 |
| Website | biosig.com |
Stock Details
| Ticker Symbol | BSGM |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001530766 |
| CUSIP Number | 09073N201 |
| ISIN Number | US09073N3008 |
| Employer ID | 26-4333375 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Karl Henry McPhie | Chief Executive Officer and Director |
| Ferdinand Groenewald | Interim Chief Financial Officer and Principal Accounting Officer |
| Mitchell Williams CFA | Chief Investment Officer |
| Lora Mikolaitis | Chief Administrative Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 13, 2025 | 424B5 | Filing |
| Aug 13, 2025 | 8-K | Current Report |
| Aug 4, 2025 | DEF 14A | Other definitive proxy statements |
| Jul 25, 2025 | SCHEDULE 13G | Filing |
| Jul 24, 2025 | PRE 14A | Other preliminary proxy statements |
| Jul 21, 2025 | 8-K/A | [Amend] Current report |
| Jul 9, 2025 | 8-K | Current Report |
| May 30, 2025 | 8-K | Current Report |
| May 27, 2025 | 8-K | Current Report |
| May 19, 2025 | 10-Q | Quarterly Report |